Article

Bausch & Lomb shareholders approve merger with Warburg Pincus affiliates

Rochester, NY-Bausch & Lomb shareholders have approved the proposed merger of the company with affiliates of Warburg Pincus LLC, according to the company.

Rochester, NY-Bausch & Lomb shareholders have approved the proposed merger of the company with affiliates of Warburg Pincus LLC, according to the company.

“We look forward to promptly completing the transaction,” said Ronald L. Zarrella, chairman and chief executive officer of Bausch & Lomb.

The deal is expected to close early in the fourth quarter. Each outstanding share of Bausch & Lomb common and Class B stock will be canceled and converted into the right to receive $65 in cash, without interest and minus any applicable withholding taxes.

Affiliates of Warburg Pincus are not required to consummate the merger until after expiration of a “marketing period” of 20 business days after the shareholder vote, which was held Sept. 21.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.